
The FDA's decision comes weeks ahead of giredestrant's scheduled approval date.
Capecitabine (Xeloda) is indicated for adjuvant colon cancer, metastatic colorectal cancer, and metastatic breast cancer.
Medication Pearl of the Day: Capecitabine (Xeloda)
Indication: Capecitabine (Xeloda) is a nucleoside metabolic inhibitor with antineoplastic activity indicated for adjuvant colon cancer, metastatic colorectal cancer, and metastatic breast cancer.
Insight:
Source:





